{"id":"S2007003617","label":"Bevacizumab","description":"","source_url":"https://id.loc.gov/authorities/subjects/sh2007003617","normalized_label":"bevacizumab","broader":["http://id.loc.gov/authorities/subjects/sh2007007759","http://id.loc.gov/authorities/subjects/sh85005650","http://id.loc.gov/authorities/subjects/sh85005714"],"aliases":["Avastin (Trademark)"],"source_identifier":"http://id.loc.gov/authorities/subjects/sh2007003617","provider":"lcsh","revision":"5a46f3e69bb73554","taxonomy_revision":"f050b5d4780b1289","title":"Bevacizumab","url":"/topics/S2007003617","kind":"topic-directory","aeo_cohort":"topic-directory","catalogue_revision":"f050b5d4780b1289","numeric_address":"13835066878856406628","address_version":"morton4x16-v1","coordinates":[0,478,33223,33792],"answer_status":"Directory metadata; local answer requires separate source review","truth_status":"Subject descriptor, not a factual answer or a demonstrated knowledge gap","reviewed_answer":null}